Neuroimmune biomarkers in schizophrenia

Schizophrenia Research

Volumn 176, Issue 1, 2016, Pages 3-13

  Tomasik, Jakub ^a,b   Rahmoune, Hassan ^a   Guest, Paul C ^a   Bahn, Sabine ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Add on treatment; Biomarker; Immune system; Personalised medicine; Schizophrenia

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 1 ANTICHYMOTRYPSIN; BIOLOGICAL MARKER; CATECHOL METHYLTRANSFERASE; CD40 ANTIGEN; CELECOXIB; CLOZAPINE; CYCLOOXYGENASE 2; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 16; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN; NEU DIFFERENTIATION FACTOR; PROSTAGLANDIN E2; PROTEIN S100B; SOLUBLE INTERLEUKIN 2 RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR;

AUTOIMMUNE DISEASE; CD4 CD8 RATIO; CLINICAL FEATURE; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION; GENETIC ASSOCIATION; GENOME-WIDE ASSOCIATION STUDY; HIGH RISK POPULATION; HUMAN; IMMUNE DYSREGULATION; IMMUNE SYSTEM; IMMUNOMODULATION; NONHUMAN; PERSONALIZED MEDICINE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRENATAL EXPOSURE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCHIZOPHRENIA; T LYMPHOCYTE; IMMUNOLOGY;

BIOMARKERS; HUMANS; SCHIZOPHRENIA;

EID: 84905532244     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.07.025     Document Type: Review

References (164)

1. Aberg, K.A., McClay, J.L., Nerella, S., Clark, S., Kumar, G., Chen, W., Khachane, A.N., Xie, L., Hudson, A., Gao, G., Harada, A., Hultman, C.M., Sullivan, P.F., Magnusson, P.K., van den Oord, E.J., Methylome-wide association study of schizophrenia: identifying blood biomarker signatures of environmental insults. JAMA Psychiatry 71:3 (2014), 255–264.
2. Akhondzadeh, S., Tabatabaee, M., Amini, H., Ahmadi Abhari, S.A., Abbasi, S.H., Behnam, B., Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr. Res. 90:1–3 (2007), 179–185.
3. Allen, A.J., Griss, M.E., Folley, B.S., Hawkins, K.A., Pearlson, G.D., Endophenotypes in schizophrenia: a selective review. Schizophr. Res. 109:1–3 (2009), 24–37.
4. Amminger, G.P., McGorry, P.D., Berger, G.E., Wade, D., Yung, A.R., Phillips, L.J., Harrigan, S.M., Francey, S.M., Yolken, R.H., Antibodies to infectious agents in individuals at ultra-high risk for psychosis. Biol. Psychiatry 61:10 (2007), 1215–1217.
5. Arion, D., Unger, T., Lewis, D.A., Levitt, P., Mirnics, K., Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biol. Psychiatry 62:7 (2007), 711–721.
6. Bayer, T.A., Buslei, R., Havas, L., Falkai, P., Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci. Lett. 271:2 (1999), 126–128.
7. Benros, M.E., Nielsen, P.R., Nordentoft, M., Eaton, W.W., Dalton, S.O., Mortensen, P.B., Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am. J. Psychiatry 168:12 (2011), 1303–1310.
8. Bergen, S.E., O'Dushlaine, C.T., Ripke, S., Lee, P.H., Ruderfer, D.M., Akterin, S., Moran, J.L., Chambert, K.D., Handsaker, R.E., Backlund, L., Osby, U., McCarroll, S., Landen, M., Scolnick, E.M., Magnusson, P.K., Lichtenstein, P., Hultman, C.M., Purcell, S.M., Sklar, P., Sullivan, P.F., Genome-wide association study in a Swedish population yields support for greater CNV and MHC involvement in schizophrenia compared with bipolar disorder. Mol. Psychiatry 17:9 (2012), 880–886.
9. Berk, M., Copolov, D., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., Judd, F., Katz, F., Katz, P., Ording-Jespersen, S., Little, J., Conus, P., Cuenod, M., Do, K.Q., Bush, A.I., N-acetyl cysteine as a glutathione precursor for schizophrenia—a double-blind, randomized, placebo-controlled trial. Biol. Psychiatry 64:5 (2008), 361–368.
10. Bianco, F.J., Lerro, F.A., Schizophrenic syndrome, thyrotoxicosis, and haloperidol. Psychosomatics 13:2 (1972), 120–121.
11. Bocchio Chiavetto, L., Boin, F., Zanardini, R., Popoli, M., Michelato, A., Bignotti, S., Tura, G.B., Gennarelli, M., Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia. Biol. Psychiatry 51:6 (2002), 480–484.
12. Boin, F., Zanardini, R., Pioli, R., Altamura, C.A., Maes, M., Gennarelli, M., Association between − G308A tumor necrosis factor alpha gene polymorphism and schizophrenia. Mol. Psychiatry 6:1 (2001), 79–82.
13. Bowden, N.A., Weidenhofer, J., Scott, R.J., Schall, U., Todd, J., Michie, P.T., Tooney, P.A., Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia. Schizophr. Res. 82:2–3 (2006), 175–183.
14. Brey, R.L., Holliday, S.L., Saklad, A.R., Navarrete, M.G., Hermosillo-Romo, D., Stallworth, C.L., Valdez, C.R., Escalante, A., del Rincon, I., Gronseth, G., Rhine, C.B., Padilla, P., McGlasson, D., Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 58:8 (2002), 1214–1220.
15. Brown, A.S., Prenatal infection as a risk factor for schizophrenia. Schizophr. Bull. 32:2 (2006), 200–202.
16. Brown, A.S., Begg, M.D., Gravenstein, S., Schaefer, C.A., Wyatt, R.J., Bresnahan, M., Babulas, V.P., Susser, E.S., Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch. Gen. Psychiatry 61:8 (2004), 774–780.
17. Brown, A.S., Hooton, J., Schaefer, C.A., Zhang, H., Petkova, E., Babulas, V., Perrin, M., Gorman, J.M., Susser, E.S., Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am. J. Psychiatry 161:5 (2004), 889–895.
18. Brown, A.S., Schaefer, C.A., Quesenberry, C.P. Jr., Liu, L., Babulas, V.P., Susser, E.S., Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. Am. J. Psychiatry 162:4 (2005), 767–773.
19. Buka, S.L., Tsuang, M.T., Torrey, E.F., Klebanoff, M.A., Bernstein, D., Yolken, R.H., Maternal infections and subsequent psychosis among offspring. Arch. Gen. Psychiatry 58:11 (2001), 1032–1037.
20. Buka, S.L., Tsuang, M.T., Torrey, E.F., Klebanoff, M.A., Wagner, R.L., Yolken, R.H., Maternal cytokine levels during pregnancy and adult psychosis. Brain Behav. Immun. 15:4 (2001), 411–420.
21. Bulut, M., Savas, H.A., Altindag, A., Virit, O., Dalkilic, A., Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia. World J. Biol. Psychiatry 10:4 Pt 2 (2009), 626–628.
22. Chakos, M., Lieberman, J., Hoffman, E., Bradford, D., Sheitman, B., Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry 158:4 (2001), 518–526.
23. Chan, M.K., Guest, P.C., Levin, Y., Umrania, Y., Schwarz, E., Bahn, S., Rahmoune, H., Converging evidence of blood-based biomarkers for schizophrenia: an update. Int. Rev. Neurobiol. 101 (2011), 95–144.
24. Chen, Y.H., Lee, H.C., Lin, H.C., Prevalence and risk of atopic disorders among schizophrenia patients: a nationwide population based study. Schizophr. Res. 108:1–3 (2009), 191–196.
25. Corvin, A., Morris, D.W., Genome-wide association studies: findings at the major histocompatibility complex locus in psychosis. Biol. Psychiatry 75:4 (2013), 276–283.
26. Craddock, R.M., Lockstone, H.E., Rider, D.A., Wayland, M.T., Harris, L.J., McKenna, P.J., Bahn, S., Altered T-cell function in schizophrenia: a cellular model to investigate molecular disease mechanisms. PLoS ONE, 2(8), 2007, e692.
27. Cross-Disorder Group of the Psychiatric Genomics Consortium; Genetic Risk Outcome of Psychosis (GROUP) Consortium, Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 381:9875 (2013), 1371–1379.
28. de Witte, L., Tomasik, J., Schwarz, E., Guest, P.C., Rahmoune, H., Kahn, R.S., Bahn, S., Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment. Schizophr. Res. 154:1-3 (2014), 23–29.
29. Dean, O., Giorlando, F., Berk, M., N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J. Psychiatry Neurosci. 36:2 (2011), 78–86.
30. Demonty, G., Bernard-Marty, C., Puglisi, F., Mancini, I., Piccart, M., Progress and new standards of care in the management of HER-2 positive breast cancer. Eur. J. Cancer 43:3 (2007), 497–509.
31. Dickerson, F., Stallings, C., Origoni, A., Vaughan, C., Khushalani, S., Yolken, R., Additive effects of elevated C-reactive protein and exposure to Herpes Simplex Virus type 1 on cognitive impairment in individuals with schizophrenia. Schizophr. Res. 134:1 (2012), 83–88.
32. Domenici, E., Wille, D.R., Tozzi, F., Prokopenko, I., Miller, S., McKeown, A., Brittain, C., Rujescu, D., Giegling, I., Turck, C.W., Holsboer, F., Bullmore, E.T., Middleton, L., Merlo-Pich, E., Alexander, R.C., Muglia, P., Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case–control collections. PLoS ONE, 5(2), 2010, e9166.
33. Doorduin, J., de Vries, E.F., Willemsen, A.T., de Groot, J.C., Dierckx, R.A., Klein, H.C., Neuroinflammation in schizophrenia-related psychosis: a PET study. J. Nucl. Med. 50:11 (2009), 1801–1807.
34. Drexhage, R.C., van der Heul-Nieuwenhuijsen, L., Padmos, R.C., van Beveren, N., Cohen, D., Versnel, M.A., Nolen, W.A., Drexhage, H.A., Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients. Int. J. Neuropsychopharmacol. 13:10 (2010), 1369–1381.
35. Drexhage, R.C., Hoogenboezem, T.A., Cohen, D., Versnel, M.A., Nolen, W.A., van Beveren, N.J., Drexhage, H.A., An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces. Int. J. Neuropsychopharmacol. 14:6 (2011), 746–755.
36. Eaton, W.W., Hayward, C., Ram, R., Schizophrenia and rheumatoid arthritis: a review. Schizophr. Res. 6:3 (1992), 181–192.
37. Eaton, W.W., Byrne, M., Ewald, H., Mors, O., Chen, C.Y., Agerbo, E., Mortensen, P.B., Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am. J. Psychiatry 163:3 (2006), 521–528.
38. Emsley, R., Chiliza, B., Asmal, L., Harvey, B.H., The nature of relapse in schizophrenia. BMC Psychiatry, 13, 2013, 50.
39. Erhardt, S., Blennow, K., Nordin, C., Skogh, E., Lindstrom, L.H., Engberg, G., Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci. Lett. 313:1–2 (2001), 96–98.
40. Ezeoke, A., Mellor, A., Buckley, P., Miller, B., A systematic, quantitative review of blood autoantibodies in schizophrenia. Schizophr. Res. 150:1 (2013), 245–251.
41. Feigenson, K.A., Kusnecov, A.W., Silverstein, S.M., Inflammation and the two-hit hypothesis of schizophrenia. Neurosci. Biobehav. Rev. 38 (2014), 72–93.
42. Fillman, S.G., Cloonan, N., Catts, V.S., Miller, L.C., Wong, J., McCrossin, T., Cairns, M., Weickert, C.S., Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol. Psychiatry 18:2 (2013), 206–214.
43. Fillman, S.G., Sinclair, D., Fung, S.J., Webster, M.J., Shannon Weickert, C., Markers of inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar disorder. Transl. Psychiatry, 4, 2014, e365.
44. Finney, G.O., Juvenile onset diabetes and schizophrenia?. Lancet 2:8673 (1989), 1214–1215.
45. Freemerman, A.J., Johnson, A.R., Sacks, G.N., Milner, J.J., Kirk, E.L., Troester, M.A., Macintyre, A.N., Goraksha-Hicks, P., Rathmell, J.C., Makowski, L., Metabolic reprogramming of macrophages: glucose transporter (GLUT1)-mediated glucose metabolism drives a pro- inflammatory phenotype. J. Biol. Chem. 289:11 (2014), 7884–7896.
46. Girgis, R.R., Kumar, S.S., Brown, A.S., The cytokine model of schizophrenia: emerging therapeutic strategies. Biol. Psychiatry 75:4 (2014), 292–299.
47. Guest, P.C., Schwarz, E., Krishnamurthy, D., Harris, L.W., Leweke, F.M., Rothermundt, M., van Beveren, N.J., Spain, M., Barnes, A., Steiner, J., Rahmoune, H., Bahn, S., Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology 36:7 (2011), 1092–1096.
48. Guest, P.C., Martins-de-Souza, D., Schwarz, E., Rahmoune, H., Alsaif, M., Tomasik, J., Turck, C.W., Bahn, S., Proteomic profiling in schizophrenia: enabling stratification for more effective treatment. Genome Med., 5(3), 2013, 25.
49. Hanninen, K., Katila, H., Rontu, R., Mattila, K.M., Hurme, M., Lehtimaki, T., Tumor necrosis factor-alpha − G308A polymorphism in schizophrenia in a Finnish population. Neurosci. Lett. 385:1 (2005), 76–81.
50. Harrison, P.J., The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122:Pt 4 (1999), 593–624.
51. He, G., Zhang, J., Li, X.W., Chen, W.Y., Pan, Y.X., Yang, F.P., Gu, N.F., Feng, G.Y., Yang, S.L., He, J.Y., Liu, B.X., Peng, Y.W., Liu, J., He, L., Interleukin-10–1082 promoter polymorphism is associated with schizophrenia in a Han Chinese sib-pair study. Neurosci. Lett. 394:1 (2006), 1–4.
52. Herberth, M., Krzyszton, D.N., Koethe, D., Craddock, M.R., Bulger, E., Schwarz, E., Guest, P., Leweke, F.M., Bahn, S., Differential effects on T-cell function following exposure to serum from schizophrenia smokers. Mol. Psychiatry 15:4 (2010), 364–371.
53. Herberth, M., Koethe, D., Cheng, T.M., Krzyszton, N.D., Schoeffmann, S., Guest, P.C., Rahmoune, H., Harris, L.W., Kranaster, L., Leweke, F.M., Bahn, S., Impaired glycolytic response in peripheral blood mononuclear cells of first-onset antipsychotic-naive schizophrenia patients. Mol. Psychiatry 16:8 (2011), 848–859.
54. Herberth, M., Rahmoune, H., Schwarz, E., Koethe, D., Harris, L.W., Kranaster, L., Witt, S.H., Spain, M., Barnes, A., Schmolz, M., Leweke, M.F., Guest, P.C., Bahn, S., Identification of a molecular profile associated with immune status in first-onset schizophrenia patients. Clin. Schizophr. Relat. Psychoses 7:4 (2014), 207–215.
55. Hu, X., Zhou, H., Zhang, D., Yang, S., Qian, L., Wu, H.M., Chen, P.S., Wilson, B., Gao, H.M., Lu, R.B., Hong, J.S., Clozapine protects dopaminergic neurons from inflammation-induced damage by inhibiting microglial overactivation. J. Neuroimmune Pharmacol. 7:1 (2012), 187–201.
56. Hwang, Y., Kim, J., Shin, J.Y., Kim, J.I., Seo, J.S., Webster, M.J., Lee, D., Kim, S., Gene expression profiling by mRNA sequencing reveals increased expression of immune/inflammation-related genes in the hippocampus of individuals with schizophrenia. Transl. Psychiatry, 3, 2013, e321.
57. Kano, S., Nwulia, E., Niwa, M., Chen, Y., Sawa, A., Cascella, N., Altered MHC class I expression in dorsolateral prefrontal cortex of nonsmoker patients with schizophrenia. Neurosci. Res. 71:3 (2011), 289–293.
58. Katila, H., Hanninen, K., Hurme, M., Polymorphisms of the interleukin-1 gene complex in schizophrenia. Mol. Psychiatry 4:2 (1999), 179–181.
59. Katz, R., Biomarkers and surrogate markers: an FDA perspective. NeuroRx 1:2 (2004), 189–195.
60. Keller, W.R., Kum, L.M., Wehring, H.J., Koola, M.M., Buchanan, R.W., Kelly, D.L., A review of anti-inflammatory agents for symptoms of schizophrenia. J. Psychopharmacol. 27:4 (2013), 337–342.
61. Khandaker, G.M., Zimbron, J., Dalman, C., Lewis, G., Jones, P.B., Childhood infection and adult schizophrenia: a meta-analysis of population-based studies. Schizophr. Res. 139:1–3 (2012), 161–168.
62. Khandaker, G.M., Zimbron, J., Lewis, G., Jones, P.B., Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. Psychol. Med. 43:2 (2013), 239–257.
63. Kirch, D.G., Kaufmann, C.A., Papadopoulos, N.M., Martin, B., Weinberger, D.R., Abnormal cerebrospinal fluid protein indices in schizophrenia. Biol. Psychiatry 20:10 (1985), 1039–1046.
64. Kirch, D.G., Alexander, R.C., Suddath, R.L., Papadopoulos, N.M., Kaufmann, C.A., Daniel, D.G., Wyatt, R.J., Blood-CSF barrier permeability and central nervous system immunoglobulin G in schizophrenia. J. Neural Transm. Gen. Sect. 89:3 (1992), 219–232.
65. Kirkpatrick, B., Miller, B.J., Inflammation and schizophrenia. Schizophr. Bull. 39:6 (2013), 1174–1179.
66. Kroken, R.A., Loberg, E.M., Dronen, T., Gruner, R., Hugdahl, K., Kompus, K., Skrede, S., Johnsen, E., A critical review of pro-cognitive drug targets in psychosis: convergence on myelination and inflammation. Front. Psychiatry, 5, 2014, 11.
67. Laan, W., Grobbee, D.E., Selten, J.P., Heijnen, C.J., Kahn, R.S., Burger, H., Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 71:5 (2010), 520–527.
68. Lavoie, S., Murray, M.M., Deppen, P., Knyazeva, M.G., Berk, M., Boulat, O., Bovet, P., Bush, A.I., Conus, P., Copolov, D., Fornari, E., Meuli, R., Solida, A., Vianin, P., Cuenod, M., Buclin, T., Do, K.Q., Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 33:9 (2008), 2187–2199.
69. Lee, S.H., Ripke, S., Neale, B.M., Faraone, S.V., Purcell, S.M., Perlis, R.H., Mowry, B.J., Thapar, A., Goddard, M.E., Witte, J.S., Absher, D., Agartz, I., Akil, H., Amin, F., Andreassen, O.A., Anjorin, A., Anney, R., Anttila, V., Arking, D.E., Asherson, P., Azevedo, M.H., Backlund, L., Badner, J.A., Bailey, A.J., Banaschewski, T., Barchas, J.D., Barnes, M.R., Barrett, T.B., Bass, N., Battaglia, A., Bauer, M., Bayes, M., Bellivier, F., Bergen, S.E., Berrettini, W., Betancur, C., Bettecken, T., Biederman, J., Binder, E.B., Black, D.W., Blackwood, D.H., Bloss, C.S., Boehnke, M., Boomsma, D.I., Breen, G., Breuer, R., Bruggeman, R., Cormican, P., Buccola, N.G., Buitelaar, J.K., Bunney, W.E., Buxbaum, J.D., Byerley, W.F., Byrne, E.M., Caesar, S., Cahn, W., Cantor, R.M., Casas, M., Chakravarti, A., Chambert, K., Choudhury, K., Cichon, S., Cloninger, C.R., Collier, D.A., Cook, E.H., Coon, H., Cormand, B., Corvin, A., Coryell, W.H., Craig, D.W., Craig, I.W., Crosbie, J., Cuccaro, M.L., Curtis, D., Czamara, D., Datta, S., Dawson, G., Day, R., De Geus, E.J., Degenhardt, F., Djurovic, S., Donohoe, G.J., Doyle, A.E., Duan, J., Dudbridge, F., Duketis, E., Ebstein, R.P., Edenberg, H.J., Elia, J., Ennis, S., Etain, B., Fanous, A., Farmer, A.E., Ferrier, I.N., Flickinger, M., Fombonne, E., Foroud, T., Frank, J., Franke, B., Fraser, C., Freedman, R., Freimer, N.B., Freitag, C.M., Friedl, M., Frisen, L., Gallagher, L., Gejman, P.V., Georgieva, L., Gershon, E.S., Geschwind, D.H., Giegling, I., Gill, M., Gordon, S.D., Gordon-Smith, K., Green, E.K., Greenwood, T.A., Grice, D.E., Gross, M., Grozeva, D., Guan, W., Gurling, H., De Haan, L., Haines, J.L., Hakonarson, H., Hallmayer, J., Hamilton, S.P., Hamshere, M.L., Hansen, T.F., Hartmann, A.M., Hautzinger, M., Heath, A.C., Henders, A.K., Herms, S., Hickie, I.B., Hipolito, M., Hoefels, S., Holmans, P.A., Holsboer, F., Hoogendijk, W.J., Hottenga, J.J., Hultman, C.M., Hus, V., Ingason, A., Ising, M., Jamain, S., Jones, E.G., Jones, I., Jones, L., Tzeng, J.Y., Kahler, A.K., Kahn, R.S., Kandaswamy, R., Keller, M.C., Kennedy, J.L., Kenny, E., Kent, L., Kim, Y., Kirov, G.K., Klauck, S.M., Klei, L., Knowles, J.A., Kohli, M.A., Koller, D.L., Konte, B., Korszun, A., Krabbendam, L., Krasucki, R., Kuntsi, J., Kwan, P., Landen, M., Langstrom, N., Lathrop, M., Lawrence, J., Lawson, W.B., Leboyer, M., Ledbetter, D.H., Lee, P.H., Lencz, T., Lesch, K.P., Levinson, D.F., Lewis, C.M., Li, J., Lichtenstein, P., Lieberman, J.A., Lin, D.Y., Linszen, D.H., Liu, C., Lohoff, F.W., Loo, S.K., Lord, C., Lowe, J.K., Lucae, S., MacIntyre, D.J., Madden, P.A., Maestrini, E., Magnusson, P.K., Mahon, P.B., Maier, W., Malhotra, A.K., Mane, S.M., Martin, C.L., Martin, N.G., Mattheisen, M., Matthews, K., Mattingsdal, M., McCarroll, S.A., McGhee, K.A., McGough, J.J., McGrath, P.J., McGuffin, P., McInnis, M.G., McIntosh, A., McKinney, R., McLean, A.W., McMahon, F.J., McMahon, W.M., McQuillin, A., Medeiros, H., Medland, S.E., Meier, S., Melle, I., Meng, F., Meyer, J., Middeldorp, C.M., Middleton, L., Milanova, V., Miranda, A., Monaco, A.P., Montgomery, G.W., Moran, J.L., Moreno-De-Luca, D., Morken, G., Morris, D.W., Morrow, E.M., Moskvina, V., Muglia, P., Muhleisen, T.W., Muir, W.J., Muller-Myhsok, B., Murtha, M., Myers, R.M., Myin-Germeys, I., Neale, M.C., Nelson, S.F., Nievergelt, C.M., Nikolov, I., Nimgaonkar, V., Nolen, W.A., Nothen, M.M., Nurnberger, J.I., Nwulia, E.A., Nyholt, D.R., O'Dushlaine, C., Oades, R.D., Olincy, A., Oliveira, G., Olsen, L., Ophoff, R.A., Osby, U., Owen, M.J., Palotie, A., Parr, J.R., Paterson, A.D., Pato, C.N., Pato, M.T., Penninx, B.W., Pergadia, M.L., Pericak-Vance, M.A., Pickard, B.S., Pimm, J., Piven, J., Posthuma, D., Potash, J.B., Poustka, F., Propping, P., Puri, V., Quested, D.J., Quinn, E.M., Ramos-Quiroga, J.A., Rasmussen, H.B., Raychaudhuri, S., Rehnstrom, K., Reif, A., Ribases, M., Rice, J.P., Rietschel, M., Roeder, K., Roeyers, H., Rossin, L., Rothenberger, A., Rouleau, G., Ruderfer, D., Rujescu, D., Sanders, A.R., Sanders, S.J., Santangelo, S.L., Sergeant, J.A., Schachar, R., Schalling, M., Schatzberg, A.F., Scheftner, W.A., Schellenberg, G.D., Scherer, S.W., Schork, N.J., Schulze, T.G., Schumacher, J., Schwarz, M., Scolnick, E., Scott, L.J., Shi, J., Shilling, P.D., Shyn, S.I., Silverman, J.M., Slager, S.L., Smalley, S.L., Smit, J.H., Smith, E.N., Sonuga-Barke, E.J., St Clair, D., State, M., Steffens, M., Steinhausen, H.C., Strauss, J.S., Strohmaier, J., Stroup, T.S., Sutcliffe, J.S., Szatmari, P., Szelinger, S., Thirumalai, S., Thompson, R.C., Todorov, A.A., Tozzi, F., Treutlein, J., Uhr, M., van den Oord, E.J., Van Grootheest, G., Van Os, J., Vicente, A.M., Vieland, V.J., Vincent, J.B., Visscher, P.M., Walsh, C.A., Wassink, T.H., Watson, S.J., Weissman, M.M., Werge, T., Wienker, T.F., Wijsman, E.M., Willemsen, G., Williams, N., Willsey, A.J., Witt, S.H., Xu, W., Young, A.H., Yu, T.W., Zammit, S., Zandi, P.P., Zhang, P., Zitman, F.G., Zollner, S., Devlin, B., Kelsoe, J.R., Sklar, P., Daly, M.J., O'Donovan, M.C., Craddock, N., Sullivan, P.F., Smoller, J.W., Kendler, K.S., Wray, N.R., Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat. Genet. 45:9 (2013), 984–994.
70. Lencz, T., Morgan, T.V., Athanasiou, M., Dain, B., Reed, C.R., Kane, J.M., Kucherlapati, R., Malhotra, A.K., Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol. Psychiatry 12:6 (2007), 572–580.
71. Leucht, S., Corves, C., Arbter, D., Engel, R.R., Li, C., Davis, J.M., Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:9657 (2009), 31–41.
72. Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Orey, D., Richter, F., Samara, M., Barbui, C., Engel, R.R., Geddes, J.R., Kissling, W., Stapf, M.P., Lassig, B., Salanti, G., Davis, J.M., Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:9896 (2013), 951–962.
73. Leweke, F.M., Gerth, C.W., Koethe, D., Klosterkotter, J., Ruslanova, I., Krivogorsky, B., Torrey, E.F., Yolken, R.H., Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 254:1 (2004), 4–8.
74. Leykin, I., Mayer, R., Shinitzky, M., Short and long-term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology 37:1 (1997), 75–86.
75. Linderholm, K.R., Skogh, E., Olsson, S.K., Dahl, M.L., Holtze, M., Engberg, G., Samuelsson, M., Erhardt, S., Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr. Bull. 38:3 (2012), 426–432.
76. Liu, J., Zhou, Y., Li, S., Li, Y., Song, X., Wang, J., Wang, L., Ying, B., Association between promoter variants of interleukin-18 and schizophrenia in a Han Chinese population. DNA Cell Biol. 30:11 (2011), 913–917.
77. Maccarrone, G., Ditzen, C., Yassouridis, A., Rewerts, C., Uhr, M., Uhlen, M., Holsboer, F., Turck, C.W., Psychiatric patient stratification using biosignatures based on cerebrospinal fluid protein expression clusters. J. Psychiatr. Res. 47:11 (2013), 1572–1580.
78. Madaan, V., Bestha, D.P., Kolli, V.B., Biological markers in schizophrenia: an update. Drugs Today (Barc.) 46:9 (2010), 661–669.
79. Maes, M., Bosmans, E., Kenis, G., De Jong, R., Smith, R.S., Meltzer, H.Y., In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr. Res. 26:2–3 (1997), 221–225.
80. Martins-de-Souza, D., Gattaz, W.F., Schmitt, A., Rewerts, C., Maccarrone, G., Dias-Neto, E., Turck, C.W., Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 259:3 (2009), 151–163.
81. Matei, I., Matei, L., Cytokine patterns and pathogenicity in autoimmune diseases. Rom. J. Intern. Med. 40:1–4 (2002), 27–41.
82. Maurizi, C.P., Influenza and schizophrenia: a possible connection with the substantia nigra. Med. Hypotheses 15:2 (1984), 163–167.
83. Meyer, U., Schwarz, M.J., Muller, N., Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol. Ther. 132:1 (2011), 96–110.
84. Miller, B.J., Buckley, P., Seabolt, W., Mellor, A., Kirkpatrick, B., Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 70:7 (2011), 663–671.
85. Miller, B.J., Gassama, B., Sebastian, D., Buckley, P., Mellor, A., Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 73:10 (2013), 993–999.
86. Muller, N., Schwarz, M., Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox. Res. 10:2 (2006), 131–148.
87. Muller, N., Schwarz, M.J., Immune system and schizophrenia. Curr. Immunol. Rev. 6:3 (2010), 213–220.
88. Muller, N., Ulmschneider, M., Scheppach, C., Schwarz, M.J., Ackenheil, M., Moller, H.J., Gruber, R., Riedel, M., COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Eur. Arch. Psychiatry Clin. Neurosci. 254:1 (2004), 14–22.
89. Muller, N., Krause, D., Dehning, S., Musil, R., Schennach-Wolff, R., Obermeier, M., Moller, H.J., Klauss, V., Schwarz, M.J., Riedel, M., Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr. Res. 121:1–3 (2010), 118–124.
90. Najjar, S., Pearlman, D.M., Alper, K., Najjar, A., Devinsky, O., Neuroinflammation and psychiatric illness. J. Neuroinflammation, 10, 2013, 43.
91. Nilsson, B.M., Hultman, C.M., Wiesel, F.A., Niacin skin-flush response and electrodermal activity in patients with schizophrenia and healthy controls. Prostaglandins Leukot. Essent. Fatty Acids 74:5 (2006), 339–346.
92. Ogah, O.S., Timeyin, A.O., Kayode, O.A., Otukoya, A.S., Akinyemi, R.O., Adeyemi, F.I., Graves' disease presenting as paranoid schizophrenia in a Nigerian woman: a case report. Cases J., 2, 2009, 6708.
93. Oken, R.J., Schulzer, M., At issue: schizophrenia and rheumatoid arthritis: the negative association revisited. Schizophr. Bull. 25:4 (1999), 625–638.
94. Ozbey, U., Tug, E., Kara, M., Namli, M., The value of interleukin-12B (p40) gene promoter polymorphism in patients with schizophrenia in a region of East Turkey. Psychiatry Clin. Neurosci. 62:3 (2008), 307–312.
95. Ozbey, U., Tug, E., Namli, M., Interleukin-10 gene promoter polymorphism in patients with schizophrenia in a region of East Turkey. World J. Biol. Psychiatry 10:4 Pt 2 (2009), 461–468.
96. Papiol, S., Rosa, A., Gutierrez, B., Martin, B., Salgado, P., Catalan, R., Arias, B., Fananas, L., Interleukin-1 cluster is associated with genetic risk for schizophrenia and bipolar disorder. J. Med. Genet. 41:3 (2004), 219–223.
97. Paul-Samojedny, M., Kowalczyk, M., Suchanek, R., Owczarek, A., Fila-Danilow, A., Szczygiel, A., Kowalski, J., Functional polymorphism in the interleukin-6 and interleukin-10 genes in patients with paranoid schizophrenia—a case–control study. J. Mol. Neurosci. 42:1 (2010), 112–119.
98. Paul-Samojedny, M., Owczarek, A., Suchanek, R., Kowalczyk, M., Fila-Danilow, A., Borkowska, P., Kucia, K., Kowalski, J., Association study of interferon gamma (IFN-gamma) + 874 T/A gene polymorphism in patients with paranoid schizophrenia. J. Mol. Neurosci. 43:3 (2011), 309–315.
99. Paul-Samojedny, M., Owczarek, A., Kowalczyk, M., Suchanek, R., Palacz, M., Kucia, K., Fila-Danilow, A., Borkowska, P., Kowalski, J., Association of interleukin 2 (IL-2), interleukin 6 (IL-6), and TNF-alpha (TNFalpha) gene polymorphisms with paranoid schizophrenia in a Polish population. J. Neuropsychiatry Clin. Neurosci. 25:1 (2013), 72–82.
100. Peters, A., The energy request of inflammation. Endocrinology 147:10 (2006), 4550–4552.
101. Potvin, S., Stip, E., Sepehry, A.A., Gendron, A., Bah, R., Kouassi, E., Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 63:8 (2008), 801–808.
102. Pramyothin, P., Khaodhiar, L., Metabolic syndrome with the atypical antipsychotics. Curr. Opin. Endocrinol. Diabetes Obes. 17:5 (2010), 460–466.
103. Prasad, K.M., Watson, A.M., Dickerson, F.B., Yolken, R.H., Nimgaonkar, V.L., Exposure to herpes simplex virus type 1 and cognitive impairments in individuals with schizophrenia. Schizophr. Bull. 38:6 (2012), 1137–1148.
104. Purcell, S.M., Wray, N.R., Stone, J.L., Visscher, P.M., O'Donovan, M.C., Sullivan, P.F., Sklar, P., Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460:7256 (2009), 748–752.
105. Radewicz, K., Garey, L.J., Gentleman, S.M., Reynolds, R., Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J. Neuropathol. Exp. Neurol. 59:2 (2000), 137–150.
106. Ramsey, J.M., Schwarz, E., Guest, P.C., van Beveren, N.J., Leweke, F.M., Rothermundt, M., Bogerts, B., Steiner, J., Bahn, S., Distinct molecular phenotypes in male and female schizophrenia patients. PLoS ONE, 8(11), 2013, e78729.
107. Rao, J.S., Kim, H.W., Harry, G.J., Rapoport, S.I., Reese, E.A., Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in the postmortem frontal cortex from schizophrenia patients. Schizophr. Res. 147:1 (2013), 24–31.
108. Ripke, S., O'Dushlaine, C., Chambert, K., Moran, J.L., Kahler, A.K., Akterin, S., Bergen, S.E., Collins, A.L., Crowley, J.J., Fromer, M., Kim, Y., Lee, S.H., Magnusson, P.K., Sanchez, N., Stahl, E.A., Williams, S., Wray, N.R., Xia, K., Bettella, F., Borglum, A.D., Bulik-Sullivan, B.K., Cormican, P., Craddock, N., de Leeuw, C., Durmishi, N., Gill, M., Golimbet, V., Hamshere, M.L., Holmans, P., Hougaard, D.M., Kendler, K.S., Lin, K., Morris, D.W., Mors, O., Mortensen, P.B., Neale, B.M., O'Neill, F.A., Owen, M.J., Milovancevic, M.P., Posthuma, D., Powell, J., Richards, A.L., Riley, B.P., Ruderfer, D., Rujescu, D., Sigurdsson, E., Silagadze, T., Smit, A.B., Stefansson, H., Steinberg, S., Suvisaari, J., Tosato, S., Verhage, M., Walters, J.T., Levinson, D.F., Gejman, P.V., Laurent, C., Mowry, B.J., O'Donovan, M.C., Pulver, A.E., Schwab, S.G., Wildenauer, D.B., Dudbridge, F., Shi, J., Albus, M., Alexander, M., Campion, D., Cohen, D., Dikeos, D., Duan, J., Eichhammer, P., Godard, S., Hansen, M., Lerer, F.B., Liang, K.Y., Maier, W., Mallet, J., Nertney, D.A., Nestadt, G., Norton, N., Papadimitriou, G.N., Ribble, R., Sanders, A.R., Silverman, J.M., Walsh, D., Williams, N.M., Wormley, B., Arranz, M.J., Bakker, S., Bender, S., Bramon, E., Collier, D., Crespo-Facorro, B., Hall, J., Iyegbe, C., Jablensky, A., Kahn, R.S., Kalaydjieva, L., Lawrie, S., Lewis, C.M., Linszen, D.H., Mata, I., McIntosh, A., Murray, R.M., Ophoff, R.A., Van Os, J., Walshe, M., Weisbrod, M., Wiersma, D., Donnelly, P., Barroso, I., Blackwell, J.M., Brown, M.A., Casas, J.P., Corvin, A.P., Deloukas, P., Duncanson, A., Jankowski, J., Markus, H.S., Mathew, C.G., Palmer, C.N., Plomin, R., Rautanen, A., Sawcer, S.J., Trembath, R.C., Viswanathan, A.C., Wood, N.W., Spencer, C.C., Band, G., Bellenguez, C., Freeman, C., Hellenthal, G., Giannoulatou, E., Pirinen, M., Pearson, R.D., Strange, A., Su, Z., Vukcevic, D., Langford, C., Hunt, S.E., Edkins, S., Gwilliam, R., Blackburn, H., Bumpstead, S.J., Dronov, S., Gillman, M., Gray, E., Hammond, N., Jayakumar, A., McCann, O.T., Liddle, J., Potter, S.C., Ravindrarajah, R., Ricketts, M., Tashakkori-Ghanbaria, A., Waller, M.J., Weston, P., Widaa, S., Whittaker, P., McCarthy, M.I., Stefansson, K., Scolnick, E., Purcell, S., McCarroll, S.A., Sklar, P., Hultman, C.M., Sullivan, P.F., Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat. Genet. 45:10 (2013), 1150–1159.
109. Roge, R., Moller, B.K., Andersen, C.R., Correll, C.U., Nielsen, J., Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far?. Schizophr. Res. 140:1–3 (2012), 204–213.
110. Rothermundt, M., Missler, U., Arolt, V., Peters, M., Leadbeater, J., Wiesmann, M., Rudolf, S., Wandinger, K.P., Kirchner, H., Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol. Psychiatry 6:4 (2001), 445–449.
111. Rothermundt, M., Falkai, P., Ponath, G., Abel, S., Burkle, H., Diedrich, M., Hetzel, G., Peters, M., Siegmund, A., Pedersen, A., Maier, W., Schramm, J., Suslow, T., Ohrmann, P., Arolt, V., Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol. Psychiatry 9:10 (2004), 897–899.
112. Ryan, M.C., Collins, P., Thakore, J.H., Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry 160:2 (2003), 284–289.
113. Saetre, P., Emilsson, L., Axelsson, E., Kreuger, J., Lindholm, E., Jazin, E., Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry, 7, 2007, 46.
114. Sainz, J., Mata, I., Barrera, J., Perez-Iglesias, R., Varela, I., Arranz, M.J., Rodriguez, M.C., Crespo-Facorro, B., Inflammatory and immune response genes have significantly altered expression in schizophrenia. Mol. Psychiatry 18:10 (2013), 1056–1057.
115. Saiz, P.A., Garcia-Portilla, M.P., Arango, C., Morales, B., Martinez-Barrondo, S., Alvarez, V., Coto, E., Fernandez, J., Bousono, M., Bobes, J., Interleukin-1 gene complex in schizophrenia: an association study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141B:6 (2006), 678–680.
116. Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium, Genome-wide association study identifies five new schizophrenia loci. Nat. Genet. 43:10 (2011), 969–976.
117. Schretlen, D.J., Vannorsdall, T.D., Winicki, J.M., Mushtaq, Y., Hikida, T., Sawa, A., Yolken, R.H., Dickerson, F.B., Cascella, N.G., Neuroanatomic and cognitive abnormalities related to herpes simplex virus type 1 in schizophrenia. Schizophr. Res. 118:1–3 (2010), 224–231.
118. Schwarcz, R., Rassoulpour, A., Wu, H.Q., Medoff, D., Tamminga, C.A., Roberts, R.C., Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry 50:7 (2001), 521–530.
119. Schwarz, E., Izmailov, R., Spain, M., Barnes, A., Mapes, J.P., Guest, P.C., Rahmoune, H., Pietsch, S., Leweke, F.M., Rothermundt, M., Steiner, J., Koethe, D., Kranaster, L., Ohrmann, P., Suslow, T., Levin, Y., Bogerts, B., van Beveren, N.J., McAllister, G., Weber, N., Niebuhr, D., Cowan, D., Yolken, R.H., Bahn, S., Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark. Insights 5 (2010), 39–47.
120. Schwarz, E., Guest, P.C., Rahmoune, H., Harris, L.W., Wang, L., Leweke, F.M., Rothermundt, M., Bogerts, B., Koethe, D., Kranaster, L., Ohrmann, P., Suslow, T., McAllister, G., Spain, M., Barnes, A., van Beveren, N.J., Baron-Cohen, S., Steiner, J., Torrey, F.E., Yolken, R.H., Bahn, S., Identification of a biological signature for schizophrenia in serum. Mol. Psychiatry 17:5 (2012), 494–502.
121. Schwarz, E., Guest, P.C., Rahmoune, H., Martins-de-Souza, D., Niebuhr, D.W., Weber, N.S., Cowan, D.N., Yolken, R.H., Spain, M., Barnes, A., Bahn, S., Identification of a blood-based biological signature in subjects with psychiatric disorders prior to clinical manifestation. World J. Biol. Psychiatry 13:8 (2012), 627–632.
122. Schwarz, E., Guest, P.C., Steiner, J., Bogerts, B., Bahn, S., Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients. Transl. Psychiatry, 2, 2012, e82.
123. Schwarz, E., van Beveren, N.J., Ramsey, J., Leweke, F.M., Rothermundt, M., Bogerts, B., Steiner, J., Guest, P.C., Bahn, S., Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathways. Schizophr. Bull. 40:4 (2014), 787–795.
124. Shi, J., Levinson, D.F., Duan, J., Sanders, A.R., Zheng, Y., Pe'er, I., Dudbridge, F., Holmans, P.A., Whittemore, A.S., Mowry, B.J., Olincy, A., Amin, F., Cloninger, C.R., Silverman, J.M., Buccola, N.G., Byerley, W.F., Black, D.W., Crowe, R.R., Oksenberg, J.R., Mirel, D.B., Kendler, K.S., Freedman, R., Gejman, P.V., Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 460:7256 (2009), 753–757.
125. Shibuya, M., Watanabe, Y., Nunokawa, A., Egawa, J., Kaneko, N., Igeta, H., Someya, T., Interleukin 1 beta gene and risk of schizophrenia: detailed case–control and family-based studies and an updated meta-analysis. Hum. Psychopharmacol. 29:1 (2014), 31–37.
126. Shirts, B.H., Wood, J., Yolken, R.H., Nimgaonkar, V.L., Comprehensive evaluation of positional candidates in the IL-18 pathway reveals suggestive associations with schizophrenia and herpes virus seropositivity. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147:3 (2008), 343–350.
127. Sinkus, M.L., Adams, C.E., Logel, J., Freedman, R., Leonard, S., Expression of immune genes on chromosome 6p21.3–22.1 in schizophrenia. Brain Behav. Immun. 32 (2013), 51–62.
128. Smyth, A.M., Lawrie, S.M., The neuroimmunology of schizophrenia. Clin. Psychopharmacol. Neurosci. 11:3 (2013), 107–117.
129. Soderlund, J., Schroder, J., Nordin, C., Samuelsson, M., Walther-Jallow, L., Karlsson, H., Erhardt, S., Engberg, G., Activation of brain interleukin-1beta in schizophrenia. Mol. Psychiatry 14:12 (2009), 1069–1071.
130. Sommer, I.E., van Westrhenen, R., Begemann, M.J., de Witte, L.D., Leucht, S., Kahn, R.S., Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr. Bull. 40:1 (2014), 181–191.
131. Song, C., Lin, A., Kenis, G., Bosmans, E., Maes, M., Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist. Schizophr. Res. 42:2 (2000), 157–164.
132. Spelman, L.M., Walsh, P.I., Sharifi, N., Collins, P., Thakore, J.H., Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet. Med. 24:5 (2007), 481–485.
133. Stefansson, H., Ophoff, R.A., Steinberg, S., Andreassen, O.A., Cichon, S., Rujescu, D., Werge, T., Pietilainen, O.P., Mors, O., Mortensen, P.B., Sigurdsson, E., Gustafsson, O., Nyegaard, M., Tuulio-Henriksson, A., Ingason, A., Hansen, T., Suvisaari, J., Lonnqvist, J., Paunio, T., Borglum, A.D., Hartmann, A., Fink-Jensen, A., Nordentoft, M., Hougaard, D., Norgaard-Pedersen, B., Bottcher, Y., Olesen, J., Breuer, R., Moller, H.J., Giegling, I., Rasmussen, H.B., Timm, S., Mattheisen, M., Bitter, I., Rethelyi, J.M., Magnusdottir, B.B., Sigmundsson, T., Olason, P., Masson, G., Gulcher, J.R., Haraldsson, M., Fossdal, R., Thorgeirsson, T.E., Thorsteinsdottir, U., Ruggeri, M., Tosato, S., Franke, B., Strengman, E., Kiemeney, L.A., Melle, I., Djurovic, S., Abramova, L., Kaleda, V., Sanjuan, J., de Frutos, R., Bramon, E., Vassos, E., Fraser, G., Ettinger, U., Picchioni, M., Walker, N., Toulopoulou, T., Need, A.C., Ge, D., Yoon, J.L., Shianna, K.V., Freimer, N.B., Cantor, R.M., Murray, R., Kong, A., Golimbet, V., Carracedo, A., Arango, C., Costas, J., Jonsson, E.G., Terenius, L., Agartz, I., Petursson, H., Nothen, M.M., Rietschel, M., Matthews, P.M., Muglia, P., Peltonen, L., St Clair, D., Goldstein, D.B., Stefansson, K., Collier, D.A., Common variants conferring risk of schizophrenia. Nature 460:7256 (2009), 744–747.
134. Steiner, J., Bielau, H., Bernstein, H.G., Bogerts, B., Wunderlich, M.T., Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. J. Neurol. Neurosurg. Psychiatry 77:11 (2006), 1284–1287.
135. Steiner, J., Mawrin, C., Ziegeler, A., Bielau, H., Ullrich, O., Bernstein, H.G., Bogerts, B., Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathol. 112:3 (2006), 305–316.
136. Steiner, J., Walter, M., Glanz, W., Sarnyai, Z., Bernstein, H.G., Vielhaber, S., Kastner, A., Skalej, M., Jordan, W., Schiltz, K., Klingbeil, C., Wandinger, K.P., Bogerts, B., Stoecker, W., Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. JAMA Psychiatry 70:3 (2013), 271–278.
137. Sullivan, P.F., Fan, C., Perou, C.M., Evaluating the comparability of gene expression in blood and brain. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141B:3 (2006), 261–268.
138. Sun, S., Wang, F., Wei, J., Cao, L.Y., Wu, G.Y., Lu, L., Kosten, T.A., Kosten, T.R., Zhang, X.Y., Association between interleukin-3 receptor alpha polymorphism and schizophrenia in the Chinese population. Neurosci. Lett. 440:1 (2008), 35–37.
139. Sun, S., Wei, J., Li, H., Jin, S., Li, P., Ju, G., Liu, Y., Zhang, X.Y., A family-based study of the IL3RA gene on susceptibility to schizophrenia in a Chinese Han population. Brain Res. 1268 (2009), 13–16.
140. Tappia, P.S., Troughton, K.L., Langley-Evans, S.C., Grimble, R.F., Cigarette smoking influences cytokine production and antioxidant defences. Clin. Sci. (Lond.) 88:4 (1995), 485–489.
141. The MHC sequencing consortium, Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium. Nature 401:6756 (1999), 921–923.
142. Torrey, E.F., Yolken, R.H., The schizophrenia–rheumatoid arthritis connection: infectious, immune, or both?. Brain Behav. Immun. 15:4 (2001), 401–410.
143. Tourjman, V., Kouassi, E., Koue, M.E., Rocchetti, M., Fortin-Fournier, S., Fusar-Poli, P., Potvin, S., Antipsychotics' effects on blood levels of cytokines in schizophrenia: a meta-analysis. Schizophr. Res. 151:1–3 (2013), 43–47.
144. Toyooka, K., Watanabe, Y., Iritani, S., Shimizu, E., Iyo, M., Nakamura, R., Asama, K., Makifuchi, T., Kakita, A., Takahashi, H., Someya, T., Nawa, H., A decrease in interleukin-1 receptor antagonist expression in the prefrontal cortex of schizophrenic patients. Neurosci. Res. 46:3 (2003), 299–307.
145. Tsuang, M., Schizophrenia: genes and environment. Biol. Psychiatry 47:3 (2000), 210–220.
146. Tsutsui, K., Kanbayashi, T., Tanaka, K., Boku, S., Ito, W., Tokunaga, J., Mori, A., Hishikawa, Y., Shimizu, T., Nishino, S., Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features. BMC Psychiatry, 12, 2012, 37.
147. Valenstein, M., Blow, F.C., Copeland, L.A., McCarthy, J.F., Zeber, J.E., Gillon, L., Bingham, C.R., Stavenger, T., Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr. Bull. 30:2 (2004), 255–264.
148. van Berckel, B.N., Bossong, M.G., Boellaard, R., Kloet, R., Schuitemaker, A., Caspers, E., Luurtsema, G., Windhorst, A.D., Cahn, W., Lammertsma, A.A., Kahn, R.S., Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol. Psychiatry 64:9 (2008), 820–822.
149. Vawter, M.P., Ferran, E., Galke, B., Cooper, K., Bunney, W.E., Byerley, W., Microarray screening of lymphocyte gene expression differences in a multiplex schizophrenia pedigree. Schizophr. Res. 67:1 (2004), 41–52.
150. Walters, J.T., Rujescu, D., Franke, B., Giegling, I., Vasquez, A.A., Hargreaves, A., Russo, G., Morris, D.W., Hoogman, M., Da Costa, A., Moskvina, V., Fernandez, G., Gill, M., Corvin, A., O'Donovan, M.C., Donohoe, G., Owen, M.J., The role of the major histocompatibility complex region in cognition and brain structure: a schizophrenia GWAS follow-up. Am. J. Psychiatry 170:8 (2013), 877–885.
151. Watanabe, Y., Someya, T., Nawa, H., Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry Clin. Neurosci. 64:3 (2010), 217–230.
152. Weiser, M., Burshtein, S., Fodoreanu, L., Chirit, R., Tala, G., Cirjaliu, D., Davis, J.M., Davidson, M., A randomized trial administering aspirin, minocycline or pramipexole vs placebo as add-on to antipsychotics in patients with schizophrenia or schizoaffecive disorder. Neuropsychopharmacology, 38, 2012, S351.
153. Wright, P., Sham, P.C., Gilvarry, C.M., Jones, P.B., Cannon, M., Sharma, T., Murray, R.M., Autoimmune diseases in the pedigrees of schizophrenic and control subjects. Schizophr. Res. 20:3 (1996), 261–267.
154. Wu, J.Q., Wang, X., Beveridge, N.J., Tooney, P.A., Scott, R.J., Carr, V.J., Cairns, M.J., Transcriptome sequencing revealed significant alteration of cortical promoter usage and splicing in schizophrenia. PLoS ONE, 7(4), 2012, e36351.
155. Wu, H.Q., Okuyama, M., Kajii, Y., Pocivavsek, A., Bruno, J.P., Schwarcz, R., Targeting kynurenine aminotransferase ii in psychiatric diseases: promising effects of an orally active enzyme inhibitor. Schizophr. Bull. 40:Suppl. 2 (2014), S152–S158.
156. Xu, M., He, L., Convergent evidence shows a positive association of interleukin-1 gene complex locus with susceptibility to schizophrenia in the Caucasian population. Schizophr. Res. 120:1–3 (2010), 131–142.
157. Xu, J., Sun, J., Chen, J., Wang, L., Li, A., Helm, M., Dubovsky, S.L., Bacanu, S.A., Zhao, Z., Chen, X., RNA-Seq analysis implicates dysregulation of the immune system in schizophrenia. BMC Genomics, 13(Suppl. 8), 2012, S2.
158. Yolken, R.H., Torrey, E.F., Lieberman, J.A., Yang, S., Dickerson, F.B., Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample. Schizophr. Res. 128:1–3 (2011), 61–65.
159. Yu, L., Yang, M.S., Zhao, J., Shi, Y.Y., Zhao, X.Z., Yang, J.D., Liu, Z.J., Gu, N.F., Feng, G.Y., He, L., An association between polymorphisms of the interleukin-10 gene promoter and schizophrenia in the Chinese population. Schizophr. Res. 71:1 (2004), 179–183.
160. Zakharyan, R., Petrek, M., Arakelyan, A., Mrazek, F., Atshemyan, S., Boyajyan, A., Interleukin-6 promoter polymorphism and plasma levels in patients with schizophrenia. Tissue Antigens 80:2 (2012), 136–142.
161. Zanardini, R., Bocchio-Chiavetto, L., Scassellati, C., Bonvicini, C., Tura, G.B., Rossi, G., Perez, J., Gennarelli, M., Association between IL-1beta -511C/T and IL-1RA (86 bp)n repeats polymorphisms and schizophrenia. J. Psychiatr. Res. 37:6 (2003), 457–462.
162. Zandi, M.S., Irani, S.R., Lang, B., Waters, P., Jones, P.B., McKenna, P., Coles, A.J., Vincent, A., Lennox, B.R., Disease-relevant autoantibodies in first episode schizophrenia. J. Neurol. 258:4 (2011), 686–688.
163. Zhai, J., Zhang, Q., Cheng, L., Chen, M., Wang, K., Liu, Y., Deng, X., Chen, X., Shen, Q., Xu, Z., Ji, F., Liu, C., Dong, Q., Chen, C., Li, J., Risk variants in the S100B gene, associated with elevated S100B levels, are also associated with visuospatial disability of schizophrenia. Behav. Brain Res. 217:2 (2011), 363–368.
164. Zhai, J., Cheng, L., Dong, J., Shen, Q., Zhang, Q., Chen, M., Gao, L., Chen, X., Wang, K., Deng, X., Xu, Z., Ji, F., Liu, C., Li, J., Dong, Q., Chen, C., S100B gene polymorphisms predict prefrontal spatial function in both schizophrenia patients and healthy individuals. Schizophr. Res. 134:1 (2012), 89–94.